Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Can individual gastrointestinal microbiome composition and diversity predict individual clinical response to anti-diabetic medication in human adults? A systematic review and narrative synthesis

  1. 1Royal College of Surgeons in Ireland – Medical University of Bahrain

Abstract

Background: Type 2 diabetes is a major worldwide barrier to healthcare and has a variable response to common anti-diabetic medication. Evidence suggests this variability may be related to the relationship between these medications and the intestinal microbiome. There are multiple different noted mechanisms by which the baseline gut microbiota can modulate anti-diabetic medication, particularly certain Bacteroides and Klebsiella species affecting metformin and acarbose action respectively.

Objective: This review aims to synthesize the available evidence on whether baseline gut microbiota composition can predict ADM efficacy in adult populations with type 2 diabetes mellitus.

Methods: A comprehensive search was performed across the major databases Embase, Cochrane, PubMed, and Scopus, focusing on studies that referenced gut microbiome and anti-diabetic medications. Included studies were randomised controlled trials, cohort studies, and case-control studies, observing recently diagnosed adult T2DM patients. The risk assessment tools used for clinical trials were ROB-2 and modified ROBINS-I for observational studies.

Results: The initial search provided 8528 papers, and in total, 6 studies were incorporated in this review. Study methodology varied greatly, resulting in vast heterogeneity, specifically in DNA extraction, sequencing protocols, and correlation methodologies. However, various patterns surfaced among the studies. Bifidobacterium, Bacteroides, and Lachnoclostridium stood out as three genera correlated with HbA1c% reduction in three of six studies.

Conclusion: Emerging evidence suggests that the gut microbiome may be associated with the efficacy of anti-diabetic medications (ADMs). However, the substantial methodological heterogeneity, relatively homogeneous study populations, and small sample sizes limit the ability to establish a robust and definitive association. Further investigation through large-scale, longitudinal studies involving diverse populations and standardised methodologies is therefore warranted to clarify the relationship between gut microbiome composition and ADM efficacy. Establishing a reproducible and clinically meaningful association could allow faecal microbiome profiling to contribute to a precision medicine approach in endocrinology.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261432018 , identifier CRD420261432018.

Related

  1. Thymus serpyllum Extract Improves Gastrointestinal Symptoms and Modulates Fecal Gut Microbiome Composition in a Multicenter, Randomized, Placebo-Controlled Clinical Trial.
    Raquel López-Zambrano, Jorge García-García, Laura López-Escánez +17
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Gastrointestinal medication use patterns and incident depressive symptoms among adults aged 50 years or older: a prospective multicohort study
    S. Wang, D. Lu, T. Tao
    medRxivPreprintAll rights reservedFull textPharmacology & toxicologymedRxivPMC
  3. From Individual Substances to the Broader Context of Substance Use.
    Ronja Järvelin, Aleksi Hupli
    Nordisk alkohol- & narkotikatidskrift : NATPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  4. Individual patient disease activity expression profiles modify the relation between disease activity and structural damage progression in RA
    EULAR rheumatology openPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Personality and Pain: An Individual-Participant Meta-Analysis of Seven Samples
    Yannick Stephan, Angelina R. Sutin, Martina Luchetti +2
    Journal of psychosomatic researchPeer-reviewedLicence not statedFull textPsychiatry & mental healthPMC
BibTeX
@article{murray2026individual,
  title = {{Can individual gastrointestinal microbiome composition and diversity predict individual clinical response to anti-diabetic medication in human adults? A systematic review and narrative synthesis}},
  author = {Paul Murray and Fazal Azizuddin and Abdelrahman Hosam Mohammed Attia and Ahmed Al Hoda and Abdulrahman Al Sadeq},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.1939093},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1939093/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Can individual gastrointestinal microbiome composition and diversity predict individual clinical response to anti-diabetic medication in human adults? A systematic review and narrative synthesis
AU  - Paul Murray
AU  - Fazal Azizuddin
AU  - Abdelrahman Hosam Mohammed Attia
AU  - Ahmed Al Hoda
AU  - Abdulrahman Al Sadeq
PY  - 2026
DA  - 2026/11/13
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1939093
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1939093/full
AB  - Background: Type 2 diabetes is a major worldwide barrier to healthcare and has a variable response to common anti-diabetic medication. Evidence suggests this variability may be related to the relationship between these medications and the intestinal microbiome. There are multiple different noted mechanisms by which the baseline gut microbiota can modulate anti-diabetic medication, particularly certain Bacteroides and Klebsiella species affecting metformin and acarbose action respectively.  Objective: This review aims to synthesize the available evidence on whether baseline gut microbiota composition can predict ADM efficacy in adult populations with type 2 diabetes mellitus.  Methods: A comprehensive search was performed across the major databases Embase, Cochrane, PubMed, and Scopus, focusing on studies that referenced gut microbiome and anti-diabetic medications. Included studies were randomised controlled trials, cohort studies, and case-control studies, observing recently diagnosed adult T2DM patients. The risk assessment tools used for clinical trials were ROB-2 and modified ROBINS-I for observational studies.  Results: The initial search provided 8528 papers, and in total, 6 studies were incorporated in this review. Study methodology varied greatly, resulting in vast heterogeneity, specifically in DNA extraction, sequencing protocols, and correlation methodologies. However, various patterns surfaced among the studies. Bifidobacterium, Bacteroides, and Lachnoclostridium stood out as three genera correlated with HbA1c% reduction in three of six studies.  Conclusion: Emerging evidence suggests that the gut microbiome may be associated with the efficacy of anti-diabetic medications (ADMs). However, the substantial methodological heterogeneity, relatively homogeneous study populations, and small sample sizes limit the ability to establish a robust and definitive association. Further investigation through large-scale, longitudinal studies involving diverse populations and standardised methodologies is therefore warranted to clarify the relationship between gut microbiome composition and ADM efficacy. Establishing a reproducible and clinically meaningful association could allow faecal microbiome profiling to contribute to a precision medicine approach in endocrinology.  Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261432018 , identifier CRD420261432018.
SN  - 1664-2392
ER  -